Open-Label, Randomized, Phase2 Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Trial Profile

Open-Label, Randomized, Phase2 Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Thrombocytopenia
  • Focus Therapeutic Use
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 01 Aug 2017 According to a CTI BioPharma media release, this trial was a condition of the clinical hold of pacritinib being removed.
    • 01 Aug 2017 According to a CTI BioPharma media release, first patient has been enrolled.
    • 30 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top